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Table. Unadjusted One-year Ischemic Event Rates Stratiﬁed by Presence or
Absence of Baseline Thrombocytopenia
Platelets
<150,000
(N [ 573)
Platelets
‡150,000
(N [ 9,996)
p-value
MACE 119 (21.3) 1458 (15.6) <0.0001
Death 36 (6.7) 320 (3.6) <0.0001
Cardiac death 20 (3.9) 205 (2.2) 0.02
Non-cardiac death 11 (2.0) 91 (1.0) 0.01
Myocardial infarction 53 (9.5) 716 (7.5) 0.06
Q wave infarction 13 (2.3) 173 (1.9) 0.34
Non-Q wave infarction 41 (7.4) 553 (5.7) 0.09
Target vessel
revascularization
61 (11.1) 786 (8.5) 0.01
Target lesion
revascularization
53 (9.6) 655 (7.2) 0.01
Deﬁnite/probable stent 15 (2.7) 228 (2.5) 0.63
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randomized 1498 patients with STEMI undergoing percutaneous coronary interven-
tion (PCI) to EES or BMS. For the purpose of this substudy, the patient-oriented
combined endpoint of all-cause death, any recurrent myocardial infarction and any
revascularization, target lesion revascularization and stent thrombosis rates were
analyzed according to the gender at 2-year follow-up.
Results: Out of 1498 patients included in the trial, 254 (17.0%) women were included
and randomized to BMS (n¼137, 53.9%) or EES (n¼117, 46.1%). Women were older
(67.9 vs. 59.8; p<0.01), had higher prevalence of hypertension (62.2% vs. 45.6%;
p<0.01) and a lower prevalence of smoking (36.6% vs. 79.5%; p<0.01) as compared
with men. Also women had a lower use of thrombectomy (59.1% vs. 66.4%; p¼0.02)
and IIb/IIIa inhibitor than men (44.9% vs. 53.9%, p<0.01). In contrast with men, stent
diameter was smaller in women (3.07 mm vs. 3.23 mm, p<0.01). Compliance of dual
antiplatelet therapy at one year was lower in women than in men. After adjustment per
confounders, the primary endpoint was similar between men and women (HR 0.95;
95%CI 0.66-1.37) and within women, between those treated with BMS versus EES
(HR 1.54: 95%CI 0.77-3.11). Women showed a lower rate of repeat revascularization
than men (HR 0.55; 95%CI 0.32-0.95) despite worse baseline characteristics. The
difference was driven by an outperformance of EES in women. No differences in
deﬁnitive/probable stent thrombosis (1.2% vs. 2.0% HR 0.58; 95%CI 0.17-1.94) was
observed between women and men.
Conclusions: Our substudy may suggest that EES would have a more potent anti-
proliferative effect in women suffering from STEMI as compared to men without any
safety concerns.
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Background: Intraprocedural thrombotic events (IPTE) during percutaneous coronary
intervention (PCI) are associated with adverse outcomes in patients with both non-ST-
segment elevation and ST-segment elevation acute coronary syndromes (NSTEACS/
STEMI). We have previously validated the occurrence of IPTE to be a powerful
independent predictor of early and late major adverse cardiac events (MACE) after
PCI. The extent to which individual components of IPTE are associated with adverse
events is unknown.
Methods: A total of 6,591 patients who received PCI for NSTEACS/STEMI in the
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) and
Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trials underwent detailed frame-by-frame core labora-
tory angiographic analysis to assess for IPTE. IPTE was deﬁned as the occurrence of
new/worsened thrombus, abrupt closure, no reﬂow/slow ﬂow, distal embolization, or
intraprocedural stent thrombosis (IPST). The independent associations of IPTE
components with death, major bleeding, and MACE at 30-days were assessed using
multivariable models.
Results: The overall incidence of IPTE was 7.8%. Among patients with IPTE, no
reﬂow/slow reﬂow was present in 58.0%, new/worsened thrombus in 35.3%, distal
embolization in 34.9%, abrupt closure in 19.8%, and IPST in 9.5% of patients. Each
IPTE component was associated with 30-day death, major bleeding, and MACE in
multivariable models (Table), with the strongest association observed for IPST.Table. Multivariate Associations of 30-day Clinical Outcomes 1 2
IPTE Component
30-day Clinical Outcome
MACE Major Bleeding Death
HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value
IPTE any 2.31 [1.76,
3.05]
<0.0001 1.94 [1.45,
2.60]
<0.0001 3.66 [2.21,
6.08]
<0.0001
New/worsened
thrombus
2.23 [1.46,
3.41]
0.0002 2.32 [1.52,
3.55]
<0.0001 5.72 [3.01,
10.86]
<0.0001
Abrupt closure 2.98 [1.98,
4.46]
0.0001 3.01 [2.00,
4.52]
<0.0001 4.83 [2.42,
9.67]
<0.0001
No reﬂow/slow
ﬂow
2.80 [2.00,
3.93]
<0.0001 2.04 [1.39,
2.99]
0.0003 4.24 [2.33,
7.72]
<0.0001
Distal
embolization
2.26 [1.48,
3.45]
0.0002 2.03 [1.31,
3.16]
0.0016 4.31 [2.15,
8.62]
<0.0001
IPST 6.21
[3.63,10.59]
<0.0001 4.81 [2.64,
8.76]
<0.0001 12.30
[5.32,28.41]
<0.0001
IPTE: Intraprocedural thrombotic event; IPST ¼ Intraprocedural stent thrombosis; MACE ¼
Major adverse cardiac events; HR ¼ Hazard Ratio; CI ¼ Conﬁdence Interval.
1 adjusted for age, gender, history of diabetes, history of hypertension, hyperlipidemia, current
smoking, prior MI, baseline hematocrit, baseline WBC count
2 each row represents a separate multivariate Cox regression model
B80 JACC Vol 62/18/Suppl B j October 2Conclusions: The occurrence of IPTE is not infrequent among high-risk ACS patients
undergoing PCI. The single component with the strongest association with adverse
events was IPST, which fortunately represented <10% of IPTE events overall. Future
therapeutic strategies aimed at minimizing the occurrence and consequences of IPTE
are warranted.
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Background: While acquired TP has consistently been associated with short- and
long-term adverse outcomes after PCI, the impact of baseline TP, however, has not
been as thoroughly investigated.
Methods: Data from 10,569 pts presenting with NSTEACS or STEMI in whom PCI
was performed was pooled from 2 large-scale randomized trials, ACUITY and
HORIZONS. Outcomes were examined according to the presence of baseline TP,
deﬁned as platelet counts <150 X 103/mm3.
Results: Baseline TP was present in 573 (5.4%) pts. Patients with baseline TP were
more likely to have diabetes, hypertension, hyperlipidemia, renal dysfunction and
prior PCI and greater number of lesions and diseased vessels. The unadjusted 1-year
rate of death (6.7% vs. 3.6%, p<0.0001), MACE (21.3% vs.15.6%, p<0.0001), target
vessel revascularization (11.1% vs. 8.5%, p¼0.01) and target lesion revascularization
(TLR; 9.6% vs. 7.2%, p¼0.01) was signiﬁcantly higher in pts with baseline TP
compared with pts with no TP. By multivariable analysis, the presence of TP at
baseline was an independent predictor of 1-year death (HR [95%CI] ¼1.71 [1.09,
2.70], p¼0.02), ischemic TLR (HR [95%CI] ¼1.42 [1.07, 1.88], p¼0.02), and major
adverse cardiac events (MACE; HR ¼1.41 [1.09, 1.82], p¼0.008).
Conclusions: The presence of baseline TP in setting of NSTEACS and STEMI pts
undergoing PCI was strongly predictive of death, ischemic TLR and MACE at 1 year.thrombosis
Data presented as n (%); CABG ¼ coronary artery bypass grafting; MACE ¼ major adverse
cardiovascular events; PCI ¼ percutaneous coronary intervention.TCT-245
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Background: Women are at high risk for mortality after ST-elevation acute
myocardial infarction (STEMI). Whether sex-disparities still exist in the treatment and
mortality of patients after STEMI remains controversial. The aim of this study was to
assess recent trends in hospital mortality and in treatment modalities for patients with
STEMI according to sex.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
